Abilify Maintena® 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1.Windsor, United Kingdom/Valby, Denmark, 27 March, 2024 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has ap...

Related Keywords

Valby ,Hovedstaden ,Denmark ,Tokyo ,Japan ,Liechtenstein ,Norway ,Iceland ,Abilify Maintena ,Peter Gillberg ,Otsuka Europe ,Johan Luthman ,European Commission ,Otsuka Pharmaceutical Company Ltd ,Otsuka Holdings Co Ltd ,Head Of Medical Affairs At Otsuka Europe ,European Union ,Otsuka Pharmaceutical Europe Ltd ,Head Of Research Development At Lundbeck ,Otsuka Pharmaceutical Europe ,Executive Vice President ,Vice President ,Medical Affairs ,Pharmaceutical Europe ,Otsuka Pharmaceutical Company ,